Brèves des congrès

LEVY Cynthia (Miami, United States) – Efficacy and Safety of Volixibat, an IBAT Inhibitor, in Patients With Primary Sclerosing Cholangitis and Moderate-to-Severe Pruritus: Results of the VISTAS Trial

SENZOLO Marco (Bologna, Italy) – Transjugular intrahepatic portosystemic shunt (TIPS) in patients with porto-sinusoidal vascular disease (PSVD): a retrospective multicenter international study from the vascular liver diseases group (VALDIG).

Charlotte Bouzbib (Paris, France) – Futility criteria for TIPS placement in patients with refractory acute variceal bleeding: a EuroTIPS study,

Javier Fernández (Barcelona, Espagne) – Plasma exchange with albumin 5% significantly increases 90-day overall survival in acute-on-chronic liver failure : top line results of the APACHE trial,

VUPPALANCHI Raj (Indianapolis, USA) – A phase 2b/3 trial of saroglitazar in primary biliary cholangitis (EPICS III)

Terry Cheuk-Fung Yip (Hong Kong, Chine) – Identifying individuals for hepatocellular carcinoma (HCC) surveillance after hepatitis B surface antigen (HBsAg) seroclearance: refining risk thresholds by age, sex, cirrhosis, diabetes and risk scores

BAIGES Anna (Barcelona, Spain) – Assessment of the Toulouse algorithm for predicting heart failure after TIPS in the EuroTIPS multicenter cohort

BISWAS Sagnik (New Delhi, India) – Olanzapine improves appetite, weight and quality of life in patients with hepatocellular carcinoma: a multicenter, randomized controlled trial

Rong Fan (Guangzhou, Chine), Liangxu Guo (Guangzhou, Chine) – A longitudinal multi-modal cfDNA framework for early detection and adaptive monitoring of hepatocellular carcinoma,

GUERRA VELOZ Maria (Londres, Royaume-Uni) – Long term survival benefits of DAA in HCV related HCC patients: results from England National HCV registry

RODRIGUEZ-PERALVAREZ Manuel (Cordoba, Spain) – Long-term outcomes of patients with complete immunosuppression withdrawal after liver transplantation: a multicentre, worldwide study

J. DONGELMANS Edo (Rotterdam, Netherlands) – Peg-IFN add-on versus nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B – a pooled analysis of two global cohorts (RETRACT-B and PROSPER studies)

MOHAMED Islam (Cleveland, USA) – Impact of glucagon-like peptide-1 therapy on alcohol-related outcomes in cirrhosis: real-world evidence from a multi-center United States cohort

SALTINI Dario (Modena, Italy) – Underdilated TIPS strategy improves survival and reduces hepatic encephalopathy in refractory ascites: a multicenter international study

STRNAD Pavel (Aachen, Germany) – RNA editing for the treatment of alpha-1 antitrypsin deficiency (AATD)

Dario Saltini (Modena, Italie) – Pulmonary hypertension phenotypes and severity independently predict non–liver -related mortality in compensated cirrhosis: applying the 2022 ESC/ERS criteria

MEDICI Valentina (Sacramento, United States) – Tiomolibdate choline stabilizes liver disease and improves neurological symptoms as well as quality-of-life in treatment experienced Wilson disease patients

Hyo Jung Park (Dallas, Etats-Unis) – Abbreviated gadoxetic acid–enhanced magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance in high-risk patients: a randomized controlled trial

Sabine Kahl (Duesseldorf, Allemagne), Effect of empagliflozin alone or combined with low-dose semaglutide on metabolic dysfunction-associated steatohepatitis and type 2 diabetes – a histology-based randomized, placebo controlled, double-blind phase 4 trial (COMBAT_T2_NASH)

Charlotte SLOOTER, Amsterdam, Netherlands – Mycophenolate mofetil in combination with prednisolone as potential first-line maintenance therapy in treatment-naïve autoimmune hepatitis: 3-year follow-up of the CAMARO-trial.

Jinlin Hou (Guangzhou, Chine), Seng Gee Lim (Singapour, Singapour), Maria Buti (Barcelone, Espagne), Man-Fung Yuen (Hong Kong, Chine), Edward J. Gane (Auckland, Nouvelle-Zélande), Pietro Lampertico (Milan, Italie), Norah Terrault (Los Angeles, Etats-Unis), Huy Nguyen (San Jose, Etats-Unis), Hyung Joon Yim (Ansan, Corée du Sud), Qing Xie (Shanghai, Chine), Jianmei Lin (Chengdu, Chine), Yunqing Qiu (Hangzhou, Chine), Rachel Wen-Juei Jeng (Linkou, Taïwan), Jeong Heo (Busan, Corée du Sud), Cheng-Yuan Peng (Taichung, Taïwan), Chien-Hung Chen (Kaohsiung, Taïwan), Wan-Long Chuang (Kaohsiung, Taïwan), Yao Xie (Beijing, Chine), Maria Hlebowicz (Olsztyn, Pologne), Nevin Idriz (Sofia, Bulgarie), Rajiv Mehta (Surat, Inde), Kosh Agarwal (Londres, Royaume-Uni), Monica Gomes da Silva (Curitiba, Brésil), Alex Franca (Aracaju, Brésil), Roxana Cernat (Constanta, Roumanie), Apinya Leerapun (Chiangmai, Thaïlande), Carla Coffin (Calgary, Canada), Adrian Gadano (Buenos Aires, Argentine), Pietro Andreone (Modena, Italie), Shigetoshi Fujiyama (Kumamoto, Japon), Vasileios Sevastianos (Athènes, Grèce), Yuichiro Suzuki (Yamanashi, Japon), Vlad Ratziu (Paris, France), Ghassan Riachi (Rouen, France), Hartmut Stocker (Berlin, Allemagne), Tien Huey Lim (Auckland, Nouvelle-Zélande), Tarik Asselah (Paris, Clichy, France), Yasuhito Tanaka (Kumamoto, Japon), Jacinta Holmes (Fitzroy, Australie), Xieer Liang (Singapour, Singapour), Jennifer Cremer (Durham, Etats-Unis), Tamara Lukic (Dubai, Émirats arabes unis), Helene Plein (Londres, Royaume-Uni), Geoff Quinn (Stevenage, Royaume-Uni), Yu Tao (Collegeville, Etat-Unis), Melanie Paff (Collegeville, Etat-Unis), Dickens Theodore (Durham, Etats-Unis), Robert Elston ((Stevenage, Royaume-Uni) – Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-Well phase 3 trials

Alvaro DIAZ-GONZALEZ, Santander, Spain – Management of patients with primary biliary cholangitis in the post-obeticholic era: real-world effectiveness data on elafibranor and seladelpar from the ColHai registry

Premashis Kar (Ghaziabad, India), Ayush Jasrotia (Ghaziabad, India), Nikhil Nagre (Ghaziabad, India), Jata Shankar Kumar (Ghaziabad, India) – A prospective, randomized, double-blind, placebo-controlled, phase III, multicenter study to evaluate the immunogenicity and safety of recombinant hepatitis-e vaccine in healthy adults & adolescents

Carlo ALESSANDRIA, Turin, Italy – Transjugular intrahepatic portosystemic shunt for refractory hepatic hydrothorax in cirrhosis: a multicenter European study

Ryan BUCHANAN, Southampton, Royaume-Uni – A multicenter randomised controlled trial of screening for MASLD in patients with type 2 diabetes not known to have liver disease in primary care.